All News
Filter News
Found 1,636 articles
-
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
8/22/2023
LAVA Therapeutics N.V. today announced recent corporate highlights and financial results for the quarter ended June 30, 2023.
-
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
8/14/2023
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update.
-
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
8/11/2023
Senti Biosciences, Inc., a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, reported financial results for the second quarter of 2023.
-
GeneFab Launches to Offer Innovative Manufacturing and Synthetic Biology Design Services for a Broad Range of Genetic Medicines
8/10/2023
GeneFab, LLC, a contract research, development and manufacturing organization partnering with the cell and gene therapy industry and backed by private equity firm Celadon Partners, LLC, announced a transaction with Senti Biosciences, Inc. in which GeneFab would sublease Senti Bio’s current good manufacturing practice facility, a portion of which is subject to certain conditions.
-
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
8/10/2023
Senti Biosciences, Inc. today announced a transaction involving GeneFab, LLC (“GeneFab”), a new independent contract manufacturing and synthetic biology biofoundry focused on next-generation cell and gene therapies backed by Celadon Partners.
-
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
8/9/2023
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2023 financial results and business updates.
-
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
8/9/2023
Mirati Therapeutics, Inc.® announced Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine -cooperative inhibitor evaluated in methylthioadenosine phosphorylase deleted cancers.
-
GT Biopharma Reports Second Quarter 2023 Financial Results
8/7/2023
GT Biopharma, Inc. today announced second quarter 2023 results for the period ended June 30, 2023.
-
Cell Expansion Market Size Will Expand around USD 50.82 Billion by 2032
8/7/2023
A report by Precedence Research examines the global cell expansion market size is estimated to reach around USD 50.82 billion by 2032 and represents a CAGR of 12.5% from 2023 to 2032.
-
CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
8/1/2023
CytoSorbents Corporation reported unaudited financial and operating results for the quarter ended June 30, 2023.
-
NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma
7/31/2023
Nanjing Leads Biolabs Co., Ltd. announced that the National Medical Products Administration and the U.S. Food and Drug Administration have approved its first-in-human Investigational New Drug applications for LBL-034, an anti-GPRC5D/CD3 bispecific antibody invented by Leads Biolabs with global intellectual property rights, for the treatment of relapsed/refractory multiple myeloma.
-
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
7/31/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
-
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
7/31/2023
Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”) today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 in combination with NKGen Biotech’s SNK01 (autologous non-genetically modified NK cells), has been accepted for a poster presentation at the ASCO Breakthrough conference from 3-5 August 2023 in Yokohama, Japan.
-
Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND
7/21/2023
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National Medical Products Administration (NMPA).
-
Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE® 327 as an Intravenous Infusion Formulation
7/20/2023
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I (R327-001) study of RECCE® 327 (R327) as an intravenous (IV) infusion formulation in 80 healthy male subjects.
-
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
7/20/2023
CatalYm announced the publication of preclinical data in Nature Communications under the title “Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment”.
-
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
7/18/2023
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA).
-
LIfT BioSciences heralds a new era of affordable effective cancer cell therapies simply produced from iPSCs
7/6/2023
LIfT BioSciences, (‘LifT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced pluripotent stem cells (iPSCs).
-
Topline results for its Daiichi Sankyo-partnered antibody-drug conjugate showed statistically significant improvement. However, AstraZeneca shares dropped around 6% in early Monday trading.
-
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
6/30/2023
Enterome announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of patients with unresectable, previously treated, metastatic colorectal cancer.